Azenta, Inc. Q3 2026 Earnings Call Summary

Moby Intelligence

Wed, August 5, 2026 at 3:30 PM GMT+3 3 min read

AZTA -3.39%

Azenta, Inc. Q3 2026 Earnings Call Summary - Moby

Operational Transformation and Performance Attribution

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Organic revenue grew 9% year-over-year, driven by strong performance in recurring revenue businesses like biorepositories and C&I, which now represent over half of total revenue.
Multiomics delivered year-over-year growth supported by strength in Europe and China, alongside modest sequential improvement in North America following targeted commercial investments.
Management is implementing a Multiomics transformation involving footprint rationalization, organizational changes, and a shift toward high-value workflows to improve long-term scalability.
Automated stores performance remained below prior year levels due to macro-driven budget constraints and slower capital equipment bookings.
Quality remediation for specific automated systems is nearing completion, with management shifting toward modular, standardized designs to reduce engineering complexity and execution risk.
The divestiture of B Medical Systems was completed on July 1, 2026, simplifying the portfolio to focus on core Life Sciences businesses.
A new AI-enabled biorepository inventory solution was deployed, improving inventory capture productivity and creating actionable digital data for customers.

Strategic Outlook and Guidance Assumptions

Full-year organic revenue outlook was raised to approximately flat to up 1%, reflecting Q3 outperformance while maintaining caution regarding uneven market recovery.
Q4 organic revenue is expected to decline low single digits due to a challenging year-over-year comparison in Multiomics, which saw record performance in Q4 2025.
Management expects the automated stores pipeline to remain variable, with revenue contribution in Q4 likely limited by uncertain project timing.
The UK Biocentre integration is expected to be 30 basis points dilutive to FY2026 margins but is projected to become accretive in FY2027 as it scales.
Capital allocation priorities remain focused on driving productivity, organic growth, disciplined M&A, and opportunistic share repurchases.

Risk Factors and Structural Transitions

Sanger sequencing continues to face structural headwinds and margin pressure due to long-term market and technology transitions.
Quality-related remediation costs for automated stores are expected to total between $5 million and $6 million for the full fiscal year 2026.
Research funding and biotechnology spending in North America remain below prior-year levels, leading to cautious capital deployment by customers.
The company repurchased 2.3 million shares for $50 million during the quarter, signaling confidence in long-term value despite current market volatility.

Q&A Session Highlights

Drivers of Multiomics improvement in North America

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Growth was driven by a catch-up of delayed projects, including NIH-funded work, and increased productivity from sales reps in their roles for 3-6 months.
The appointment of a new Vice President of Sales for North America is expected to further bridge execution gaps in the region.

EBITDA margin bridge and non-recurring costs

Management identified approximately $5 million in quality issues and $5 million in strategic investments as non-recurring items impacting the FY2026 'resting heart rate'.
Q4 margins will be impacted by higher bonus accruals following the Q3 revenue beat and accelerated digital commercial investments.

Strategic shift to modular automated stores

The company is moving away from highly customized 'N of 1' systems toward configurable modular designs to eliminate quality loops and standardize customer needs.
New R&D structures have been established with dedicated teams for new product introduction, sustaining engineering, and proof of concept.

Long-term margin expansion and LRP targets

Management reaffirmed the long-range plan (LRP) target of 18% to 20% adjusted EBITDA margins, noting that expansion will likely accelerate in FY2028 and FY2029.
The company expects margin flow-through to be more meaningful in FY2027 as cost optimization actions in stores and Sanger sequencing take effect.